Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $11.9200 (-0.58%) ($11.6800 - $12.3400) on Wed. Apr. 29, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.37% (three month average) | RSI | 65 | Latest Price | $11.9200(-0.58%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.1% a day on average for past five trading days. | Weekly Trend | TGTX advances 10% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(63%) ARKG(57%) ARKK(54%) IBB(54%) IBUY(52%) | Factors Impacting TGTX price | TGTX will decline at least -3.685% in a week (0% probabilities). VIXM(-33%) VXX(-31%) UUP(-14%) TLT(-1%) IYT(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.685% (StdDev 7.37%) | Hourly BBV | 0 () | Intraday Trend | -3.2% | | | |
|
5 Day Moving Average | $12.56(-5.1%) | 10 Day Moving Average | $12.29(-3.01%) | 20 Day Moving Average | $11.11(7.29%) | To recent high | -25.5% | To recent low | 66.9% | Market Cap | $1.51b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |